Sandoz Omnitrope Gains First “Similar Biological” Positive Opinion In the EU
This article was originally published in The Pink Sheet Daily
Executive Summary
Recombinant-DNA growth hormone would be approved through new pathway by demonstrating comparable safety and efficacy to Genotropin.
You may also be interested in...
Health Canada To Consider Follow-On Biologics Proposal In May
"Subsequent Entry Biologics" would not automatically receive indications held by the reference product, draft guidance says.
Health Canada To Consider Follow-On Biologics Proposal In May
"Subsequent Entry Biologics" would not automatically receive indications held by the reference product, draft guidance says.
Hospira, Stada Collaboration To Yield Biosimilar EPO In The EU Ahead Of U.S.
Hospira obtains exclusive distribution rights for Bioceuticals erythropoietin in the EU and will be solely responsible for U.S. development.